A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Atezolizumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms OAK
- Sponsors Roche
- 01 Dec 2023 Results assessing the transcriptomic analysis with multiplex immunohistofluorescence (mIHF) on tumor tissue and with proteomic profiling of plasma from patients included in the open-label, randomized phase 2 POPLAR (NCT01903993) and phase 3 OAK trials (NCT02008227), which evaluated atezolizumab versus docetaxel in patients with NSCLC who progressed following platinum-based chemotherapy, published in the Clinical Cancer Research.
- 24 Oct 2023 Results (n=412) assessing the modified Glasgow prognostic score (mGPS) at the time of first staging (6 weeks after the start of therapy) in patients with non-small cell lung cancer treated with atezolizumab, presented at the 48th European Society for Medical Oncology Congress.
- 06 Jun 2023 Results demonstrating the atezolizumab response score (ARS), uses digital pathology features of the shape and size of nuclei in the tumor epithelium to predict response to atezolizumab in patients from POPLAR and OAK trials with non-small cell lung cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.